A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.

Also called NCT03499704

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 133 participants (enrolled count) (from the registry)
Sponsor
Celltrion Pharm, Inc. (from the registry)
Registry
  • NCT NCT03499704
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03499704. Randomized; no masking; primary purpose treatment. Start 2020-02-11 (actual); primary completion 2024-01-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
Acronym
EPIDOTE
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Pioglitazone + Alogliptin
Intervention (Drug)
Alogliptin
Intervention (Drug)
Metformin
Intervention (Drug)
Dapagliflozin
Lead sponsor
Celltrion Pharm, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03499704
Content hash
74fd786735c14713897292a20e769f0f7f1d51d6ee7400655ad1404c724a6c00